After Prometheus Loss, High Court Eyes Cancer Gene Patent

Law360, New York (March 22, 2012, 5:38 PM EDT) -- Now that the U.S. Supreme Court has invalidated Prometheus Laboratories Inc.'s blood testing method patents, the life sciences patent spotlight shifts to a case over the validity of breast cancer genes isolated by Myriad Genetics Inc., which the high court could decide whether to hear within days.

On Wednesday, the day after its highly-anticipated decision in Mayo v. Prometheus, the high court placed the Myriad case on its conference schedule for Friday. That indicates the justices could decide by Monday whether to grant certiorari in the...
To view the full article, register now.